RP-1
- Generic Name
- RP-1
An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma
- Conditions
- Advanced Melanoma
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Replimune Inc.
- Registration Number
- NCT06590480
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)
- Conditions
- Advanced Melanoma
- Interventions
- Drug: Single-agent chemotherapy
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Replimune Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT06264180
- Locations
- πΊπΈ
Duke Cancer Center, Durham, North Carolina, United States
πΊπΈThomas Jefferson University, Philadelphia, Pennsylvania, United States
πΊπΈFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1.
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Sherrif Ibrahim
- Target Recruit Count
- 12
- Registration Number
- NCT05858229
- Locations
- πΊπΈ
Rochester Dermatologic Surgery, Victor, New York, United States
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
- Conditions
- Advanced Cutaneous Squamous Cell CarcinomaMetastatic Cutaneous Squamous Cell CarcinomaCutaneous Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Replimune Inc.
- Target Recruit Count
- 231
- Registration Number
- NCT04050436
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
π«π·CHU Besancon - Hopital Jean Minjoz, Besancon, France
π©πͺUniversitatsklinikum Heidelberg: National Centre for Tumour Diseases (NCT), Heidelberg, Germany
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
- Conditions
- Non-melanoma Skin CancerMicrosatellite InstabilityCancerMismatch Repair DeficiencyCutaneous MelanomaNSCLCMelanoma (Skin)
- Interventions
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Replimune Inc.
- Target Recruit Count
- 340
- Registration Number
- NCT03767348
- Locations
- πΊπΈ
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
πΊπΈProvidence Portland Medical Center, Portland, Oregon, United States
πΊπΈMUSC Health, Charleston, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.